China Clinical Trial for Therapeutic MR-HIFU Ablation of Uterine Fibroids
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention |
|---|---|
| Uterine Fibroids | Device: MR-HIFU uterine fibroid treatment |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | China Clinical Trial for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids |
- Change in fibroid volume [ Time Frame: At baseline and at 6 months after treatment ]Proportion of patients with treated fibroid volume at 6 months after treatment reduced to 90% or less of treated fibroid volume at baseline (before MR-HIFU treatment)
- Adverse Events [ Time Frame: Within 6 months after treatment ]Number of Adverse Events reported as resulting from MR-HIFU treatment
| Enrollment: | 107 |
| Study Start Date: | May 2012 |
| Study Completion Date: | May 2015 |
| Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: MR-HIFU Treatment
Patients in this arm will receive MR-HIFU uterine fibroid treatment
|
Device: MR-HIFU uterine fibroid treatment
A single treatment session for uterine fibroids with the MR-HIFU device.
Other Name: Philips Sonalleve MR-HIFU
|
Detailed Description:
This study is to confirm the safety and effectiveness of Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) in ablating uterine tissue associated with symptomatic leiomyomas. The importance of this therapy is that it offers a non-invasive, uterine sparing procedure for the treatment of uterine fibroids in pre- and peri- menopausal women.
MR-HIFU uses ultrasound to heat and thermally ablate fibroid tissue. The MRI system identifies the ultrasound path and monitors heat rise in the fibroid tissue. The goal of the study is to show treatment safety and effectiveness of the Philips Sonalleve MR-HIFU device for uterine fibroids marketing approval in the Chinese market. MR-HIFU will be performed in 100 patients who pass inclusion/exclusion criteria. Safety, quality of life, and imaging endpoints will be evaluated in all study patients at baseline and at 6 months post-treatment. All patients will be followed up for 12 months post-treatment for safety.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women, age between 18 and 55 years
- Weight < 140 kg
- Pre- or peri-menopausal
- Uterine size < 24 weeks
- Cervical cell assessment by Pap smear/Thin-prep Cytologic Test (TCT): Normal, Low Grade Squamous Intraepithelial Lesion (SIL), Low risk Human Papillomavirus (HPV) or Atypical Squamous Cells of Uncertain Significance (ASCUS) subtypes of cervical tissue
-
Fibroids selected for treatment meeting the following criteria:
- Total planned ablation volume of all fibroids should not exceed 250 ml, and
- No more than 5 fibroids should be planned for ablation, and
- Dominant fibroid (diameter) is greater than or equal to 3 cm, and
- Fibroids which are completely non-enhancing under Magnetic Resonance (MR) contrast agent should not be treated as the identification of treated volume becomes ambiguous
- Highly perfused or brighter than myometrium in T2-weighted MRI (according to the T2 contrast obtained using the Philips MR-HIFU protocol) fibroids should not be treated
- MR-HIFU device accessibility to fibroids such that at least 50% of the total fibroid volume can be treated
- Willing and able to attend all study visits
Exclusion Criteria:
- Other pelvic disease (Other mass, endometriosis, ovarian tumor, acute pelvic disease, significant adenomyosis)
- Desire for future pregnancy
- Significant systemic disease, even if controlled
- Positive pregnancy test
- Hematocrit < 25%
- Extensive scarring along anterior lower abdominal wall (> 50% of area)
- Surgical clips in the direct path of the HIFU beam
- MRI contraindicated
- MRI contrast agent contraindicated
- Fibroids not quantifiable on MRI (e.g. multi-fibroid cases where volume measurements are not feasible)
- Calcifications around or throughout uterine tissues
- Communication barrier
- Suspected malignancy
Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01588899
| China, Beijing | |
| Peking University First Hospital | |
| Beijing, Beijing, China | |
| China | |
| First Affiliated Hospital of Medical College of Xi'an Jiaotong University | |
| Xi'an, China | |
| Principal Investigator: | Qinping Liao | Peking University First Hospital |
| Principal Investigator: | Yueling Wang | First Affiliated Hospital Xi'an Jiaotong University |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Philips Healthcare |
| ClinicalTrials.gov Identifier: | NCT01588899 History of Changes |
| Other Study ID Numbers: |
907764 |
| First Submitted: | April 27, 2012 |
| First Posted: | May 1, 2012 |
| Last Update Posted: | October 22, 2015 |
| Last Verified: | October 2015 |
Keywords provided by Philips Healthcare:
|
Uterine Leiomyomas Fibroids HIFU Ablation High Intensity Focused Ultrasound |
Additional relevant MeSH terms:
|
Leiomyoma Myofibroma Neoplasms, Muscle Tissue Neoplasms, Connective and Soft Tissue |
Neoplasms by Histologic Type Neoplasms Neoplasms, Connective Tissue Connective Tissue Diseases |